SecBot SecBot

GALT

GALECTIN THERAPEUTICS INC
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001133416 Biotech & Drug Discovery
$3.19 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $3.19
Market cap
$341.6M
Small cap
Median target
$11.00
+245% · range $11.00–11.00
Next earnings
Nov 16
in 20 days · EPS est. −$0.05
1 year
−37.5%
from $5.10 · Oct 27
30 days
−18.8%
from $3.93
52-week range
$2.08–6.51
−51% from high · low May 19
Avg volume 20D
212.9K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$520.9K
1 buyer · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 1 bearish · 3 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 5/6 ·Next Earnings date, Nov 16, 2026
Strongest BULLISH Galectin Therapeutics announced it submitted a registrational Phase 3 protocol for belapectin (MASH…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $810.00 at an average $2.70. 2 insiders sold $521.7K. Price is 18% above their cost.

  • InstitutionsMIXED

    Q2 2026: 11 added (0 new), 8 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.100 → −$0.050 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED2,988,353$13.9M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,308,394$6.1M
MARSHALL WACE, LLPTRIM831,010$3.9M
STATE STREET CORPDOUBLED567,779$2.6M
NORTHERN TRUST CORPDOUBLED386,545$1.8M
CITADEL ADVISORS LLCTRIM198,701$922.0K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM177,197$822.2K
CHARLES SCHWAB INVESTMENT MANAGEMENT INCDOUBLED116,424$540.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +245%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jun 23, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$810.00
bought · 1 insider
$521.7K
sold · 2 insiders
+18.1%
vs their $2.70 cost
DateInsiderTypeValue
Jul 31, 2026
Uihlein Richard E
Director
EXERCISE$95.5M
Jul 31, 2026
Uihlein Richard E
Director
EXERCISE$10.3M
Jul 31, 2026
Uihlein Richard E
Director
EXERCISE$9115.6T
Jul 31, 2026
Uihlein Richard E
Director
EXERCISE$106.7T
Jul 14, 2026
Jamil Khurram
Chief Medical Officer
EXERCISE$49.4K
Jul 14, 2026
Jamil Khurram
Chief Medical Officer
SELL$83.3K
Jun 29, 2026
Jamil Khurram
Chief Medical Officer
EXERCISE$118.7K
Jun 29, 2026
Jamil Khurram
Chief Medical Officer
SELL$239.2K

Earnings setup

Estimates
Nov 16
reports in 20 days
−$0.05
EPS estimate, this quarter
+50%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.05-$0.05–-$0.05+50.0%$0.00
Next Q-$0.05-$0.05–-$0.05+50.0%$0.00
Current FY-$0.30-$0.30–-$0.30+18.9%$0.00
Next FY-$0.23-$0.23–-$0.23+30.3%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 13, 2026 SEC
Galectin Therapeutics filed DEFA14A definitive additional proxy soliciting materials on October 13, 2026, in…
DEFA14A — Impact 5/10
Oct 13, 2026 SEC
Galectin Therapeutics filed its definitive proxy statement for the 2026 annual meeting, seeking shareholder approval…
DEF 14A — Impact 6/10
Oct 6, 2026 Press
Galectin Therapeutics announced it submitted a registrational Phase 3 protocol for belapectin (MASH cirrhosis/portal…
Impact 7/10
Oct 6, 2026 FDA
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the lea
Aug 14, 2026 SEC
Galectin Therapeutics reported Q2 2026 net loss of $9.2M ($0.14/share) vs $7.6M ($0.12/share) a year ago, but the…
PRESS-RELEASE — Impact 8/10
Jul 31, 2026 Insider
Uihlein Richard E acquired via exercise 31,825,235 shares
Director @ $3.00 ($95.5M)
Jul 31, 2026 Insider
Uihlein Richard E acquired via exercise 2,550,932 shares
Director @ $4.05 ($10.3M)
Jul 31, 2026 Insider
Uihlein Richard E acquired via exercise 95,475,705 shares
Director @ $95,475,705.00 ($9115.6T)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
GALT Q3 2026 Earnings Scheduled — 2026-11-16
Recent
Oct 6, 2026
FDA
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
Aug 17, 2026
Earnings date
GALT Q2 2026 Earnings Scheduled — 2026-08-17
Aug 14, 2026
Earnings
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
Aug 12, 2026
Earnings date
GALT Q2 2026 Earnings Scheduled — 2026-08-12
Aug 4, 2026
Press release
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock

SecBot reports

10 filings · 1 press release · 3 bullish · 1 bearish · 2 mixed · 4 neutral
All GALT filing & press-release reports (11)